Provided by Tiger Trade Technology Pte. Ltd.

Takeda Pharmaceutical Co Ltd

18.27
+0.28501.59%
Volume:605.30K
Turnover:11.08M
Market Cap:58.13B
PE:-57.36
High:18.41
Open:18.23
Low:18.18
Close:17.98
52wk High:18.90
52wk Low:12.99
Shares:3.18B
Float Shares:3.09B
Volume Ratio:1.29
T/O Rate:0.02%
Dividend:0.62
Dividend Rate:3.42%
EPS(TTM):-0.3184
EPS(LYR):-0.3042
ROE:-2.26%
ROA:2.69%
PB:1.23
PE(LYR):-60.03

Loading ...

Takeda ordered by pay hundreds of millions in antitrust case, Bloomberg says

TIPRANKS
·
May 19

Justice Department announces $13.67M civil settlement with Takeda

TIPRANKS
·
May 15

Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million

Dow Jones
·
May 15

Takeda to cut about 4,500 jobs in fiscal 2026 as it steps up restructuring

Reuters
·
May 14

Takeda's Next Wave Of Drugs Has Investors Watching Closely

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Q4 Adj. EPS $0.28 Beats $0.21 Estimate, Sales $6.978B Miss $7.050B Estimate

Benzinga Earnings
·
May 13

Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook

MT Newswires Live
·
May 13

Press Release: Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results

Dow Jones
·
May 13

Takeda Pharmaceutical Co Ltd expected to post earnings of JPY117.96 a share - Earnings Preview

Reuters
·
May 11

Immigration Uncovers Trading Scam in Batam, 210 Foreigners Nabbed

Tempo
·
May 09

Takeda Advances TAK-279 Into Phase 2a Crohn’s Study, Signaling Long-Term GI Growth Ambitions

TIPRANKS
·
May 08

Takeda Advances Pediatric ENTYVIO Study, Supporting Long-Term Growth Potential

TIPRANKS
·
May 08

Earning Preview: Takeda Pharmaceutical Co Ltd revenue is expected to increase by 6.75% this quarter, and institutional views are constructive

Earnings Agent
·
May 06

Takeda Says Phase 2/3 Trial of TAK-881 Meets Endpoint in Primary Immunodeficiency Disease

MT Newswires Live
·
May 04

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

MT Newswires Live
·
Apr 28

Takeda Targets Older Adults With New Dengue Vaccine Study, Eyeing Long-Term Market Upside

TIPRANKS
·
Apr 24

Takeda’s TAK-505 Trial Marks a New Bet on Difficult Solid Tumors

TIPRANKS
·
Apr 24

Takeda Extends Pediatric Entyvio Data: What Long-Term Safety Tracking Means for TAK Investors

TIPRANKS
·
Apr 17

Takeda upgraded to Outperform from Market Perform at Bernstein

TIPRANKS
·
Apr 08

Denali Therapeutics Regains Full Rights to Dementia Drug Following Takeda Partnership Termination

MT Newswires Live
·
Apr 06